Illinois Municipal Retirement Fund Purchases 30,511 Shares of Halozyme Therapeutics, Inc. $HALO

Illinois Municipal Retirement Fund boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 50.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 90,977 shares of the biopharmaceutical company’s stock after purchasing an additional 30,511 shares during the period. Illinois Municipal Retirement Fund’s holdings in Halozyme Therapeutics were worth $5,880,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Allworth Financial LP increased its holdings in shares of Halozyme Therapeutics by 322.5% during the 3rd quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock worth $2,914,000 after acquiring an additional 30,331 shares during the last quarter. Element Squared LLC bought a new stake in Halozyme Therapeutics in the 4th quarter valued at $1,193,000. CWA Asset Management Group LLC acquired a new stake in Halozyme Therapeutics during the 4th quarter valued at $907,000. Assenagon Asset Management S.A. acquired a new stake in Halozyme Therapeutics during the 4th quarter valued at $4,851,000. Finally, Paragon Capital Management Inc. bought a new position in Halozyme Therapeutics during the fourth quarter worth $1,273,000. Institutional investors own 97.79% of the company’s stock.

Insider Activity

In related news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the firm’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total transaction of $153,397.71. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $61,245,810.60. This represents a 0.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 74,102 shares of company stock valued at $5,205,798. 2.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on HALO shares. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. UBS Group restated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Morgan Stanley decreased their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Finally, Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Stock Performance

HALO opened at $77.81 on Friday. The business has a fifty day simple moving average of $72.03 and a 200 day simple moving average of $70.20. The company has a market capitalization of $9.23 billion, a PE ratio of 27.99, a price-to-earnings-growth ratio of 0.32 and a beta of 0.84. Halozyme Therapeutics, Inc. has a 1 year low of $55.64 and a 1 year high of $82.26. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.